PL4376832T3 - Obicetrapib do stosowania w leczeniu chorób sercowo-naczyniowych (cvd) u pacjentów wykazujących słabą odpowiedź na leczenie his - Google Patents

Obicetrapib do stosowania w leczeniu chorób sercowo-naczyniowych (cvd) u pacjentów wykazujących słabą odpowiedź na leczenie his

Info

Publication number
PL4376832T3
PL4376832T3 PL22754412.9T PL22754412T PL4376832T3 PL 4376832 T3 PL4376832 T3 PL 4376832T3 PL 22754412 T PL22754412 T PL 22754412T PL 4376832 T3 PL4376832 T3 PL 4376832T3
Authority
PL
Poland
Prior art keywords
hyporesponders
obicetrapib
cvd
treating
cardiovascular disease
Prior art date
Application number
PL22754412.9T
Other languages
English (en)
Inventor
Johannes Jacob Pieter KASTELEIN
Marc DITMARSCH
Michael Harvey Davidson
Original Assignee
Newamsterdam Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B.V. filed Critical Newamsterdam Pharma B.V.
Publication of PL4376832T3 publication Critical patent/PL4376832T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
PL22754412.9T 2021-07-26 2022-07-25 Obicetrapib do stosowania w leczeniu chorób sercowo-naczyniowych (cvd) u pacjentów wykazujących słabą odpowiedź na leczenie his PL4376832T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21187721 2021-07-26
PCT/EP2022/070780 WO2023006657A1 (en) 2021-07-26 2022-07-25 Treatment of his hyporesponders

Publications (1)

Publication Number Publication Date
PL4376832T3 true PL4376832T3 (pl) 2026-08-10

Family

ID=77358089

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22754412.9T PL4376832T3 (pl) 2021-07-26 2022-07-25 Obicetrapib do stosowania w leczeniu chorób sercowo-naczyniowych (cvd) u pacjentów wykazujących słabą odpowiedź na leczenie his

Country Status (17)

Country Link
US (1) US20230041138A1 (pl)
EP (2) EP4376832B1 (pl)
JP (1) JP2024527023A (pl)
KR (1) KR20240040767A (pl)
CN (1) CN117940125A (pl)
AU (1) AU2022320869A1 (pl)
CA (1) CA3227153A1 (pl)
DK (1) DK4376832T3 (pl)
ES (1) ES3071242T3 (pl)
FI (1) FI4376832T3 (pl)
IL (1) IL310115A (pl)
LT (1) LT4376832T (pl)
MX (1) MX2024001170A (pl)
PL (1) PL4376832T3 (pl)
PT (1) PT4376832T (pl)
TW (1) TWI922719B (pl)
WO (1) WO2023006657A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2025146415A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
EP4746866A1 (en) * 2024-09-17 2026-05-27 NewAmsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026146129A1 (en) * 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Magnesium salts of obicetrapib
WO2026146132A1 (en) * 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Salts of obicetrapib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
KR20150028233A (ko) 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-3 지방산의 조성물
CN107108558B (zh) 2014-08-12 2019-11-19 狄智玛制药私人有限公司 制备用于制备四氢喹啉衍生物的合成中间体的方法
MX376135B (es) * 2014-08-28 2025-03-04 Newamsterdam Pharma B V Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa

Also Published As

Publication number Publication date
JP2024527023A (ja) 2024-07-19
CA3227153A1 (en) 2023-02-02
AU2022320869A1 (en) 2024-02-01
TW202310842A (zh) 2023-03-16
CN117940125A (zh) 2024-04-26
US20230041138A1 (en) 2023-02-09
DK4376832T3 (da) 2026-06-15
WO2023006657A1 (en) 2023-02-02
PT4376832T (pt) 2026-06-11
EP4789665A1 (en) 2026-08-12
TWI922719B (zh) 2026-04-21
IL310115A (en) 2024-03-01
LT4376832T (lt) 2026-07-10
KR20240040767A (ko) 2024-03-28
ES3071242T3 (en) 2026-06-22
MX2024001170A (es) 2024-05-14
FI4376832T3 (fi) 2026-06-10
EP4376832A1 (en) 2024-06-05
EP4376832B1 (en) 2026-03-25